Codexis, Inc. (CDXS) Stock
Key stats
- Market cap
- $106.92M
- Price / Earnings ratio
- -3.6x
- EPS (TTM)
- -$0.33
- Volume
- Loading
- 52-week high
- $2.98
- 52-week low
- $0.96
Source: third-party data provider, as of November 13, 2026
Compare with CDXS
Recent news

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
CDXS

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
CDXS

Codexis Q2 Earnings Call Highlights
Codexis Q2 Earnings Call Highlights
CDXS

Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
CDXS
Technical indicators
- RSI 14
- 32.23
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.02
- SMA 50
- $1.31
- Price below SMA 50
- EMA 50
- $1.32
- Price below EMA 50
- SMA 200
- $1.79
- Price below SMA 200
- EMA 200
- $1.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
CDXS

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
CDXS

Codexis Q2 Earnings Call Highlights
Codexis Q2 Earnings Call Highlights
CDXS

Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
CDXS

Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CDXS

Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now
Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now
CDXS
About Codexis, Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Alison Moore Ph.D. | President, CEO & Director | 1967 |
| Ms. Georgia L. Erbez | CFO & Chief Business Officer | 1967 |
| Dr. Stefan Lutz Ph.D. | Chief Scientific Officer | — |
| Mr. Britton Jimenez | Senior Vice President of Sales & Marketing | — |
| Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources | — |
| Mr. John Schiffhauer | Senior Vice President of Intellectual Property | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 32.23
- MACD 12/26/9
- -0.09
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.02
- SMA 50
- $1.31
- Price below SMA 50
- EMA 50
- $1.32
- Price below EMA 50
- SMA 200
- $1.79
- Price below SMA 200
- EMA 200
- $1.65
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.2 | -7.4 | ||||||||||
| 2022 | -35.8 | -3.7 | +5.0 | -45.0 | -15.8 | +4.4 | -36.9 | +4.2 | -12.6 | -7.4 | -4.0 | -17.2 |
| 2023 | +31.7 | -24.8 | -10.6 | -3.7 | -45.4 | +16.7 | +32.4 | -47.3 | +5.0 | -16.2 | +42.2 | +23.5 |
| 2024 | -15.7 | +68.5 | -24.3 | -16.6 | +8.7 | -10.9 | +7.0 | |||||
| 2026 | +49.2 | +3.7 | -15.4 | -41.4 | +17.2 | -7.9 | -12.5 | -6.7 |



